Paratek Pharmaceuticals, Inc. – NASDAQ:PRTK
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Paratek Pharmaceuticals stock price monthly change
+0.91%
month
Paratek Pharmaceuticals stock price quarterly change
+1.83%
quarter
Paratek Pharmaceuticals stock price yearly change
-7.08%
year
Paratek Pharmaceuticals key metrics
Market Cap | 127.82M |
Enterprise value | 366.11M |
P/E | -2.25 |
EV/Sales | 1.95 |
EV/EBITDA | -5.14 |
Price/Sales | 0.75 |
Price/Book | -0.82 |
PEG ratio | -0.88 |
EPS | -1.19 |
Revenue | 167.74M |
EBITDA | -43.39M |
Income | -67.12M |
Revenue Q/Q | 38.13% |
Revenue Y/Y | 65.99% |
Profit margin | -52.95% |
Oper. margin | -39.06% |
Gross margin | 83.21% |
EBIT margin | -39.06% |
EBITDA margin | -25.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeParatek Pharmaceuticals stock price history
Paratek Pharmaceuticals stock forecast
Paratek Pharmaceuticals financial statements
| Sep 2022 | 27.84M | -25.26M | -90.75% |
|---|---|---|---|
| Dec 2022 | 72.62M | -7.15M | -9.85% |
| Mar 2023 | 29.20M | -20.14M | -68.96% |
| Jun 2023 | 38.06M | -14.55M | -38.23% |
| 2023-11-02 | -0.25 | -0.38 |
|---|
| Sep 2022 | 157321000 | 323.47M | 205.61% |
|---|---|---|---|
| Dec 2022 | 172538000 | 343.58M | 199.13% |
| Mar 2023 | 150828000 | 339.86M | 225.33% |
| Jun 2023 | 145792000 | 347.15M | 238.12% |
| Sep 2022 | -12.41M | 0 | 1K |
|---|---|---|---|
| Dec 2022 | -20.11M | 30M | -2.72M |
| Mar 2023 | 11.09M | -32K | -280K |
| Jun 2023 | -1.77M | 0 | -565K |
Paratek Pharmaceuticals alternative data
| Aug 2023 | 268 |
|---|---|
| Sep 2023 | 268 |
| Oct 2023 | 268 |
| Nov 2023 | 268 |
| Dec 2023 | 268 |
| Jan 2024 | 268 |
| Feb 2024 | 268 |
| Mar 2024 | 268 |
| Apr 2024 | 268 |
| May 2024 | 268 |
| Jun 2024 | 268 |
| Jul 2024 | 268 |
Paratek Pharmaceuticals other data
51.39%
-21.64%
of PRTK is owned by hedge funds
35
-42
27.94M
-12.33M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2022 | 0 | 27266 |
| Dec 2022 | 0 | 286009 |
| Feb 2023 | 0 | 14000 |
| Mar 2023 | 788500 | 0 |
| Aug 2023 | 0 | 142346 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BRENNER RANDALL B. officer: Chief Development & Re.. | Common Stock | 27,603 | $2.2 | $60,727 | ||
Sale | BIGHAM MICHAEL director, officer: Exec. Chairm.. | Common Stock | 31,250 | $2.2 | $68,750 | ||
Sale | HASKEL WILLIAM M. officer: CLO, General Counsel &.. | Common Stock | 34,526 | $2.2 | $75,957 | ||
Sale | LOH EVAN director, officer.. | Common Stock | 48,967 | $2.2 | $107,727 | ||
Sale | LOH EVAN director, officer.. | Common Stock | 48,967 | $2.2 | $107,727 | ||
Purchase | DONDERO JAMES D 10 percent owner | Common Stock | 100,000 | $1.73 | $173,000 | ||
Purchase | DONDERO JAMES D 10 percent owner | Common Stock | 106,000 | $1.77 | $187,620 | ||
Purchase | DONDERO JAMES D 10 percent owner | Common Stock | 242,500 | $1.74 | $421,950 | ||
Purchase | DONDERO JAMES D 10 percent owner | Common Stock | 105,137 | $1.4 | $147,192 | ||
Purchase | DONDERO JAMES D 10 percent owner | Common Stock | 234,863 | $1.5 | $352,295 |
| Patent |
|---|
Application Filling date: 4 Jan 2021 Issue date: 23 Dec 2021 |
Application Filling date: 3 Sep 2019 Issue date: 11 Nov 2021 |
Application Filling date: 5 Jan 2021 Issue date: 29 Apr 2021 |
Application 9-Aminomethyl Minocycline Compounds And Use Thereof In Treating Community-Acquired Bacterial Pneumonia (CABP) Filling date: 4 Nov 2020 Issue date: 25 Feb 2021 |
Application Filling date: 5 Apr 2019 Issue date: 21 Jan 2021 |
Grant Utility: 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) Filling date: 10 Jul 2019 Issue date: 17 Nov 2020 |
Application Filling date: 24 Feb 2020 Issue date: 22 Oct 2020 |
Application Filling date: 17 Jan 2020 Issue date: 17 Sep 2020 |
Application Filling date: 6 Dec 2019 Issue date: 10 Sep 2020 |
Application CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(ME- THYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-- 2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME Filling date: 15 May 2019 Issue date: 23 Jan 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 16 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 3 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 3 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Evan Loh (1959) Chief Executive Officer & Director | $1,030,000 |
Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA (1958) Executive Chairman | $899,700 |
| Mr. Adam Woodrow (1967) Pres & Chief Commercial Officer | $711,870 |
-
When is Paratek Pharmaceuticals's next earnings date?
Unfortunately, Paratek Pharmaceuticals's (PRTK) next earnings date is currently unknown.
-
Does Paratek Pharmaceuticals pay dividends?
No, Paratek Pharmaceuticals does not pay dividends.
-
How much money does Paratek Pharmaceuticals make?
Paratek Pharmaceuticals has a market capitalization of 127.82M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.67% to 150.79M US dollars. Paratek Pharmaceuticals made a loss 63.57M US dollars in net income (profit) last year or -$0.38 on an earnings per share basis.
-
What is Paratek Pharmaceuticals's stock symbol?
Paratek Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PRTK".
-
What is Paratek Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Paratek Pharmaceuticals?
Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Paratek Pharmaceuticals's key executives?
Paratek Pharmaceuticals's management team includes the following people:
- Dr. Evan Loh Chief Executive Officer & Director(age: 66, pay: $1,030,000)
- Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA Executive Chairman(age: 67, pay: $899,700)
- Mr. Adam Woodrow Pres & Chief Commercial Officer(age: 58, pay: $711,870)
-
How many employees does Paratek Pharmaceuticals have?
As Jul 2024, Paratek Pharmaceuticals employs 268 workers.
-
When Paratek Pharmaceuticals went public?
Paratek Pharmaceuticals, Inc. is publicly traded company for more then 16 years since IPO on 3 Feb 2009.
-
What is Paratek Pharmaceuticals's official website?
The official website for Paratek Pharmaceuticals is paratekpharma.com.
-
Where are Paratek Pharmaceuticals's headquarters?
Paratek Pharmaceuticals is headquartered at 75 Park Plaza, Boston, MA.
-
How can i contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals's mailing address is 75 Park Plaza, Boston, MA and company can be reached via phone at +61 78076600.
Paratek Pharmaceuticals company profile:
Paratek Pharmaceuticals, Inc.
paratekpharma.comExchange:
NASDAQ
Full time employees:
268
Industry:
Biotechnology
Sector:
Healthcare
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
75 Park Plaza
Boston, MA 02116
Boston, MA 02116
CIK: 0001178711
ISIN: US6993743029
CUSIP: 699374302
